Jacobson Pharma Corporation Limited (02633) released its monthly return for the period ended 30 November 2025. The authorized share capital stood at 5,000,000,000 ordinary shares at a par value of HKD 0.01, amounting to HKD 50,000,000 in total. No changes were reported in the authorized share capital during the month.

As of the end of November 2025, the number of issued ordinary shares remained at 2,000,221,000, with no treasury shares recorded. There were no increases or decreases in the Company’s issued shares or treasury shares over the reporting period.

Regarding its share option scheme, the maximum potential issuance remained at 138,000,000 shares, with no exercise of options and no funds raised for the month. The Company confirmed compliance with the relevant listing rules and regulatory requirements throughout the reporting period.